Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Double shampooing daily is safe and helps manage oily scalp and dandruff without causing hair loss. Accutane is considered for reducing sebum production despite potential temporary hair loss.

After jaw surgery caused intense hair shedding and scalp itch, using pyrilutamide significantly reduced these symptoms. It's suggested to test pyrilutamide for authenticity before use, despite positive personal experience with the product from MV Supplements.

The new Kirkland Minoxidil appears different, being more oily and lacking crystallization, leading to confusion about its authenticity. Users suggest ordering directly from Costco to ensure getting the genuine product.

The user switched from topical Minoxidil and Finasteride to oral Finasteride and reduced testosterone, expecting to lower DHT, but instead, DHT increased and hair loss worsened. The user is seeking advice on whether to return to the previous topical treatment or if others have experienced similar issues with oral Finasteride while on TRT.

The user experienced high estradiol levels after using topical finasteride at 0.1 mg/day, which normalized after discontinuation. They are questioning if this low dosage could significantly impact hormone levels.

The conversation is about finding reputable clinics in Belgium, the Netherlands, France, or Germany for PRP with double centrifugation or exosome therapy for hair loss. The user seeks recommendations based on personal experiences or good reviews.

A 27-year-old man shared his hormonal panel results after one year of taking finasteride 1mg/day for hair loss, showing his DHT levels nearly doubled. He reported stabilized hair loss with mild side effects that resolved, and he is considering a hair transplant but is concerned about the increased DHT levels and potential treatment options.

A Korean laser helmet increases hair growth by 44% compared to a placebo. Users discuss its cost-effectiveness, clinical support, and compare it to treatments like finasteride and minoxidil, focusing on wavelength and energy density.

The conversation is about the double standard in the hair loss community regarding shedding when using different treatments. The conclusion is that shedding is considered normal when starting finasteride or minoxidil, but not when starting dutasteride, despite the fact that dutasteride is more effective at reducing DHT.

The user is using a hair loss treatment regimen that includes double the recommended dose of Minoxidil foam once nightly, a mix of RU58841 and stemoxydine after the Minoxidil dries, ketoconazole every other day, and weekly microneedling with alternating depths. They are also considering starting finasteride soon.

The devastating effects of male pattern baldness and how it can be seen as a societal double standard, with many people mocking those who experience hair loss. People shared their own experiences of hair loss and discussed potential treatments such as hair transplants, Minoxidil, finasteride, and RU58841.

A dermatologist recommended a new supplement containing annurca apple, which reportedly doubles hair density and increases keratin after 60 days, to be used with finasteride. Some users are skeptical, considering it potentially ineffective or a marketing ploy, while others are open to trying it if it proves effective and affordable.

Finasteride is seen as risky for men due to side effects like erectile dysfunction, while hormonal birth control for women is normalized despite its side effects. The discussion points out a double standard influenced by societal and gender norms.

The user switched from finasteride and topical minoxidil to dutasteride and oral minoxidil due to side effects but is experiencing further hair recession. They plan to double the dosage, despite mixed feedback on the effectiveness and potential side effects of the treatments.

Hair loss's social impact, focusing on Will Smith defending Jada Pinkett Smith's alopecia. The conversation highlights double standards between men and women experiencing hair loss and emphasizes empathy.

Person shared 7-month progress of hair growth using finasteride, minoxidil, and nizoral shampoo. Happy with results, experienced minimal shedding, and applies double dose of minoxidil at night.

Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. Conversation highlights double standards with hair fibers and women's wigs/makeup/extensions/eyelashes.

A 28-year-old started using finasteride and minoxidil for hair loss and is frustrated by insensitive comments from others about his balding, which is a sensitive topic for him. People, including a girl he's seeing, have made hurtful remarks, and the conversation includes discussions on societal double standards and advice to ignore such comments and focus on self-improvement.

The trial for TDM-105795 has been completed, and it was in phase 2A. The discussion seeks input on the next phases, 2B or 3, based on safety and efficacy.

The conversation is about a user considering joining a clinical study for Clascoterone (Breezula) after experiencing no results with topical finasteride and minoxidil, and side effects from oral finasteride. The user is seeking advice on clinical study participation and experiences.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.

A user is joining a clinical trial for Clascoterone, a drug approved for acne but being tested for hair loss. They previously tried finasteride with limited success and plan to share updates on their experience with the new treatment.

A clinical trial for hair loss treatments involving Minoxidil, Finasteride, and RU58841, and when the results of the trial will be available.

A 34-year-old male shares his 4-month progress using Minoxidil 5%, Finasteride 0.2% liquid, Tretinoin 0.01% liquid, and a dermaroller once a week for hair regrowth, reporting no side effects and noticing baby hairs on the crown. He prefers topical treatments over oral Finasteride and is optimistic about further progress.

A user experienced no visible improvement in hair loss after 10 months on 0.5mg finasteride and increased the dose to 1mg, noticing a possible shedding phase. They also use topical minoxidil, ketoconazole shampoo, and dermastamping, and are seeking others' experiences with similar treatments.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. Users are asked to share their experiences with Pyri/Koshine.

A user shared progress pictures showing significant hair growth after 7 months of using 1mg finasteride and 2.5mg minoxidil. The user also noted improved beard growth.

The FDA will now require only one clinical trial for drug approval, potentially speeding up the release of hair loss treatments like PP405. Pelage is expected to present full results of PP405 Phase 2a trials and move to Phase III in mid-2026.